BioNTech upgraded to “buy” at UBS as next-gen cancer drugs de-risk

Investing.com Gold reports: BioNTech upgraded to “buy” at UBS as next-gen cancer drugs de-risk. Full body text was unavailable at ingest time, so this brief is based on headline context.